Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pharmaust Limited ( (AU:NUZ) ) has shared an update.
Neurizon Therapeutics Limited has applied for quotation on the ASX of 9,500,000 new ordinary fully paid shares under the code NUZ, with an issue date of 19 March 2026. The application, lodged as an Appendix 2A, progresses the formal listing of these securities, potentially expanding the company’s tradeable capital base and liquidity for investors.
The move follows a previously announced transaction under an Appendix 3B, indicating these shares are part of an earlier capital initiative rather than a new fundraising round. By advancing the quotation of these securities, Neurizon is consolidating its capital structure on the market, which may support future corporate or development activities in its therapeutics portfolio.
The most recent analyst rating on (AU:NUZ) stock is a Hold with a A$0.08 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
More about Pharmaust Limited
Neurizon Therapeutics Limited is a biotechnology company listed on the ASX under the code NUZ. The company operates in the therapeutics sector, focusing on the development of medical treatments, although the specific indications or products are not detailed in the filing.
Average Trading Volume: 639,596
Technical Sentiment Signal: Sell
Current Market Cap: A$55.89M
For an in-depth examination of NUZ stock, go to TipRanks’ Overview page.